Fig. 2

Effects of Ricolinostat on megakaryocytic differentiation of HSPCs. A Absolute counts of total nucleated cells at day 7 of Ricolinostat treatment were calculated and normalized to the initial HSPCs. B CFSE time series obtained from cells at the end of the first stage. All cells obtained from the first stage were labeled with CFSE on the first day of the second stage (day 0). CFSE fluorescence intensity was detected by flow cytometry for 7 consecutive days. C Flow cytometry analysis of CD34, CD41a, and CD61 expression in cells on day 7 of Ricolinostat treatment. D Percentage of CD34⁺CD41a⁺ cells on day 7 of Ricolinostat treatment. E Percentage of CD41a⁺CD61⁺ cells on day 7 of Ricolinostat treatment. F Absolute counts of CD34⁺CD41a⁺ cells on day 7 of Ricolinostat treatment were calculated and normalized to the initial HSPCs. G Absolute counts of CD41a⁺CD61⁺ cells on day 7 of Ricolinostat treatment were calculated and normalized to initial HSPCs. Results are expressed as the mean ± SEM from three independent experiments. Unpaired Student’s t-test, *p < 0.05; **p < 0.01